Free tool
FAERS Monitor: Tnkase
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103909 or its brand name (Tnkase, Tenecteplase). Reports on generic versions are filed under their own applications.
Reports
1,600
Serious
1,196
75% of reports
Hospitalization
437
Death reported
375
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use412
- no adverse event316
- cerebral haemorrhage162
- angioedema129
- haemorrhage intracranial118
- death81
- haemorrhage81
- drug ineffective72
- cerebrovascular accident71
- haemorrhagic transformation stroke61
- subarachnoid haemorrhage47
- medication error40
- hypotension39
- cardiogenic shock34
- cardiac arrest33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 31 |
| 2006 | 12 |
| 2007 | 25 |
| 2008 | 15 |
| 2009 | 37 |
| 2010 | 14 |
| 2011 | 32 |
| 2012 | 55 |
| 2013 | 56 |
| 2014 | 28 |
| 2015 | 18 |
| 2016 | 16 |
| 2017 | 78 |
| 2018 | 48 |
| 2019 | 44 |
| 2020 | 55 |
| 2021 | 74 |
| 2022 | 101 |
| 2023 | 168 |
| 2024 | 345 |
| 2025 | 177 |
| 2026 | 146 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemorrhagic transformation strokeSignal | 61 | 555.1 | 431.7 | 31,844 |
| haemorrhage intracranialSignal | 118 | 104.6 | 87.8 | 11,915 |
| subarachnoid haemorrhageSignal | 47 | 60.9 | 45.9 | 2,699 |
| cerebral haemorrhageSignal | 162 | 59.8 | 51.6 | 9,274 |
| angioedemaSignal | 129 | 38.4 | 32.6 | 4,664 |
| cardiogenic shockSignal | 34 | 31.2 | 22.4 | 963 |
| no adverse eventSignal | 316 | 23.0 | 20.8 | 6,663 |
| haemorrhageSignal | 81 | 10.2 | 8.2 | 665 |
| medication errorSignal | 40 | 9.5 | 7.0 | 295 |
| off label useSignal | 412 | 6.2 | 5.7 | 1,863 |
| cerebrovascular accidentSignal | 71 | 5.5 | 4.4 | 260 |
| cardiac arrestSignal | 33 | 5.3 | 3.7 | 110 |
| hypotensionSignal | 39 | 2.6 | 1.9 | 36 |
| death | 81 | 1.2 | 1.0 | 4 |
| drug ineffective | 72 | 0.7 | 0.6 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.